SMMT vs. JANX, INDV, EVO, MOR, ACAD, MLTX, RYTM, MRUS, CORT, and IDYA
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Janux Therapeutics (JANX), Indivior (INDV), Evotec (EVO), MorphoSys (MOR), ACADIA Pharmaceuticals (ACAD), MoonLake Immunotherapeutics (MLTX), Rhythm Pharmaceuticals (RYTM), Merus (MRUS), Corcept Therapeutics (CORT), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical preparations" industry.
Summit Therapeutics (NASDAQ:SMMT) and Janux Therapeutics (NASDAQ:JANX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.
Summit Therapeutics received 264 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 58.82% of users gave Janux Therapeutics an outperform vote while only 56.91% of users gave Summit Therapeutics an outperform vote.
4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 83.7% of Summit Therapeutics shares are held by insiders. Comparatively, 35.4% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summit Therapeutics has a net margin of 0.00% compared to Janux Therapeutics' net margin of -721.18%. Janux Therapeutics' return on equity of -17.88% beat Summit Therapeutics' return on equity.
Summit Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 125.99%. Janux Therapeutics has a consensus target price of $61.33, suggesting a potential upside of 31.56%. Given Summit Therapeutics' higher possible upside, research analysts clearly believe Summit Therapeutics is more favorable than Janux Therapeutics.
In the previous week, Summit Therapeutics had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 4 mentions for Summit Therapeutics and 1 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.73 beat Summit Therapeutics' score of 0.59 indicating that Janux Therapeutics is being referred to more favorably in the news media.
Summit Therapeutics has a beta of -1.21, indicating that its stock price is 221% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 4.18, indicating that its stock price is 318% more volatile than the S&P 500.
Janux Therapeutics has higher revenue and earnings than Summit Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Janux Therapeutics beats Summit Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
